Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CVCEL-SCI Corporation logo

CEL-SCI Corporation (CVM)

New York Stock Exchange Arca · Currency in USD
$1.64 ▲ +0.03 (+1.86%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.59 ▼ -0.05 (-3.05%)
After hours: Oct 23, 6:23 PM ET

Summary

Previous Close
$1.61
Open
$1.59
Day's Range
$1.57 – $1.64
52 Week Range
$0.89 – $9.35
Volume
41,894
Avg. Volume
277,083
Market Cap
$28.85M
Beta (5Y Monthly)
0.59
PE Ratio (TTM)
--
EPS (TTM)
-$1.87
Earnings Date
Dec 23, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
Aug 28, 1996
1y Target Est
--

Profile: CEL-SCI Corporation

Sector
Healthcare
Industry
Biotechnology
Full-time employees
43
CEO
Geert R. Kersten

CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology.

Earnings

Next report: Wed, Dec 23, 2026
DateEst.Actual
Aug 14, 2026–-$0.47
May 18, 2026–-$0.67
Feb 17, 2026–-$0.68
Dec 29, 2025–-$0.76
Aug 14, 2025–-$1.36
May 14, 2025–-$2.40

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on CVM and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.